There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. After-hours trades for Mirum Pharmaceuticals Inc. (MIRM) shows that investor sentiment remained broken, with the stock’s consolidated last price falling by -$0.50, or -1.75%, to $28.01. The Mirum Pharmaceuticals Inc. has recorded 4,922 volume in the after hours trading session. Recently, Yahoo Finance discussed the stock, revealing that Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences.
This NASDAQ-listed company operates within the Biotechnology industry segment, falling under the Healthcare sector. At the end of the last regular session, the stock closed at $28.51 and fluctuated between $28.75 as its day high and $27.38 as its day low. The current market capitalization of Mirum Pharmaceuticals Inc. is $1.09B. A total of 0.55 million shares were traded on the day, compared to an average of 537.78K shares.
Insider trades can also provide insight into a stock’s future direction. During the recent three months, MIRM has seen 11 BUY and 23 SELL insider trades, representing the acquisition of 257,213 and the disposition of 18,264,875 shares. Over the last 12 months, there were 25 BUYs and 25 SELLs from insiders. Insiders purchased 360,511 shares during that period but sold 18,453,604.
In the most recent transaction, Heron Patrick J bought 147,991 shares of MIRM for 26.25 per share on Aug 31. After the transaction, the Director now owns 147,991 company shares. In a previous transaction on Aug 25, Howe Jolanda sold 3,459 shares at 26.23 per share. MIRM shares that SVP, Global Controller owns now total 0.
Among the insiders who sold shares, Peetz Christopher disposed of 5,498 shares on Jul 03 at a per-share price of $25.65. This resulted in the President and CEO holding 115,334 shares of MIRM after the transaction. In another insider transaction, Vig Pamela sold 1,425 shares at $25.65 per share on Jul 03. Company shares held by the Head of Research & Development now total 30,786.
Even though price targets are rarely accurate, they do tend to exert some kind of influence from time to time and are often considered important by markets. According to analysts who have offered 12-month price targets for MIRM in the last 3 months, the mean price target is $52.00 with high estimates of $84.00 and low estimates of $34.00. In terms of 52-week highs and lows, MIRM has a high of $30.39 and a low of $17.32.
As of this writing, MIRM has an earnings estimate of -$1.48 per share for the current quarter. EPS was calculated based on a consensus of 5 estimates, with a high estimate of -$0.12 per share and a lower estimate of -$5.17. The company reported an EPS of -$0.8 in the last quarter, which was 14.90% higher than expectations of -$0.94.
Balance Sheet Annually/Quarterly
In a balance sheet, you can see what assets and liabilities the company has, as well as how much equity investors have invested. These figures can be used to calculate a company’s financial ratios to give investors a better idea of its prospects. MIRM’s latest balance sheet shows that the firm has $156.54M in Cash & Short Term Investments as of fiscal 2021. There were $2.61M in debt and $42.60M in liabilities at the time. Its Book Value Per Share was $2.06, while its Total Shareholder’s Equity was $120.21M.
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for MIRM is Buy with a score of 5.00.